DSGN
What one share of Design Therapeutics holds
Pharmaceutical Preparations
We are a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC® molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations.
Design Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$1.18 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.92 |
| Cash and investments | $3.31 |
| Book value | $3.23 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $0.01 | −$0.52 | $0.00 | −$0.55 | — | −$0.71 |
| 2021 | — | −$0.77 | $0.03 | −$0.67 | — | $6.89 |
| 2022 | — | −$1.14 | $0.02 | −$0.94 | — | $5.86 |
| 2023 | — | −$1.19 | $0.00 | −$1.05 | — | $4.92 |
| 2024 | $0.00 | −$0.88 | $0.01 | −$0.77 | — | $4.27 |
| 2025 | $0.00 | −$1.22 | $0.00 | −$0.95 | — | $3.52 |